eligibility_summary
Adults 18–75 with confirmed CD20+ primary CNS DLBCL (brain/spinal cord/eyes/meninges), no systemic disease, treatment‑naïve except brief low‑dose dexamethasone, ECOG 0–3, MRI‑measurable lesion ≥1 cm, life expectancy ≥3 mo, consent/follow‑up, contraception required. Exclude: systemic lymphoma, prior chemo/RT/HSCT, other active malignancy, active infection (HBV/HCV/HIV) or abnormal labs, uncontrolled comorbidity, pregnancy/lactation, abuse/noncompliance, allergy, GI malabsorption, MRI contraindication.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I/II single-arm trial in newly diagnosed primary CNS lymphoma (CD20+ DLBCL) testing: 1) Pomalidomide (oral immunomodulatory drug, IMiD, cereblon E3 ligase modulator) that induces degradation of Ikaros/Aiolos (IKZF1/3), enhances T/NK-cell activation and cytokine signaling, has anti-angiogenic effects, and can trigger lymphoma cell apoptosis, 2) Rituximab (anti-CD20 chimeric monoclonal antibody) depleting B cells via ADCC, CDC, and apoptosis, 3) High-dose Methotrexate (antimetabolite antifolate, DHFR inhibitor) blocking thymidylate/purine synthesis to kill rapidly dividing cells and penetrate the CNS. Targets/pathways: malignant CD20+ B cells in CNS, CRBN–IKZF1/3 axis, CD20-mediated immune effector mechanisms, and folate/DHFR-dependent DNA synthesis.